Introduction: Low back pain is the greatest cause of years lived with disability worldwide, and is linked with high societal and economic burden. Neuromuscular control impairments are a common clinical presentation in patients with non-specific low back pain. Musculoskeletal physiotherapists commonly use feedback as a part of the management of low back disorders. This systematic review will aim to assess the effectiveness of extrinsic biofeedback for reducing pain, disability and recurrence of pain in patients with non-specific low back pain.
F o r p e e r r e v i e w o n l y F o r p e e r r e v i e w o n l y F o r p e e r r e v i e w o n l y F o r p e e r r e v i e w o n l y 3
Strengths and limitations of this study:
• This review will be the first to systematically, and comprehensively assess the effects of extrinsic feedback in the management of low back pain
• Findings from this research will identify areas for future research in the field
• Comprehensive and exhaustive search for relevant studies from several databases
• This review is limited to evidence from randomized controlled trials
• No language restrictions will be imposed The accepted clinical sub-category of non-specific low back pain is a multifactorial disorder, and defined as "pain and discomfort, localised below the costal margin and above the inferior gluteal folds, with or without referred leg pain". [3] The one month prevalence of low back pain is 23.2%. [2] Patients with non-specific low back pain present with poor recovery. [4] Non-specific LBP is influenced by biological, psychological and social factors. [5] These three factors interact and impact on symptoms onset, recovery and clinical outcomes of patients with LBP. [6] Biological factors include impaired motor control, [7] delayed muscle activity of lumbopelvic muscles, [8] reduced postural strategies for maintaining balance.
[9] Psychological factors may hinder recovery (e.g. fear avoidance, and depressive symptoms) [10] and be associated with higher pain levels (e.g. negative beliefs).
[11] Social factors such as family environment, socioeconomic and educational status and religion may modulate pain reported by patients with low back pain. [12] Management of non-specific low back pain commonly focuses on education, pain control [13] and targeting neuromuscular impairments. [14] When targeting neuromuscular impairments, musculoskeletal physiotherapists may use extrinsic feedback to help patients improve movement and control awareness of lumbo-pelvic muscles. [15] Extrinsic feedback can be defined as any form of information provided to the patient that originates from an external source (e.g. mirror, pressure biofeedback, tactile or verbal input by the clinician). [16 17 ] The way extrinsic feedback is provided to patients can hinder or improve motor control. [18] Our previous review assessed how extrinsic feedback was provided to patients in trials and found that the majority of the studies did not adopt ideal forms of feedback provision. [17] A recent review reported that extrinsic feedback combined with physiotherapy compared to physiotherapy alone was superior for pain, but did not improve disability levels in patients with neck pain. [19] Currently, the effectiveness of extrinsic feedback for the management of patients with non-specific low back pain is unknown. The aim of the proposed systematic review is to assess the effectiveness of extrinsic biofeedback for reducing pain, disability and recurrence of pain in patients with non-specific low back pain.
Methods

Design
This study will be a systematic review with meta-analysis, if data allow, and will be based on the PRISMA-P checklist. [20] F o r p e e r r e v i e w o n l y 5 
Types of studies
We will include randomised controlled trials, and exclude narrative reviews, systematic reviews, non-randomised clinical trials, cross sectional studies and observational studies. We will not impose language restrictions.
Types of participants
Studies must have recruited symptomatic individuals with non-specific low back pain (acute, subacute or chronic), aged between 18 and 65 years. We will exclude studies involving patients with specific or systematic diseases (e.g. tumours, cauda equina syndrome, fracture, inflammatory arthropathy).
Types of interventions
Any interventions that include the use of any form of extrinsic biofeedback (e.g. pressure biofeedback, electromyography feedback, body positional biofeedback, or other type of feedback) will be included in this review. We will exclude studies focusing on behavioural feedback or ergonomic training. Studies must include at least one of the following comparators:
Extrinsic feedback vs. placebo or control
Extrinsic feedback vs another form of established effective intervention
Extrinsic feedback + intervention vs. intervention alone
Types of outcome measures
We will consider the following primary outcome measures: (1) pain must be measured with visual analogue scale, numeric pain scale or any other validated instrument; (2) disability levels must be measured with validated instruments (e.g. Oswestry, Quebec Back Pain Disability Scale, the Roland-Morris Disability Questionnaire); (3) recurrence of LBP (as reported by patients or assessed by a clinical researcher). We will consider motor performance tests as secondary outcomes. Motor performance must be assessed using a form of biofeedback or electromyography pre-and post-intervention.
Searches
Systematic searches will be performed in the following databases from the inception: CINAHL, Embase, Medline, PsycInfo, Scopus and Web of Science. Search strategy is presented in Table 1 . This search strategy was developed in consultation with a health sciences librarian, tested and used for a review previously conducted by our research team. [17] After the exclusion of duplicates, two independent reviewers will conduct title, abstract and full text screening against inclusion criteria. If any disagreement persists, a third reviewer will adjudicate. The reference lists of included studies will be screened for additional relevant studies.
Data extraction and management
Data will be extracted by two reviewers independently and compared. If any disagreements persist and cannot be resolved by consensus, a third reviewer will be consulted. We will extract the following data: authors, year of publication, country of origin, study design, study purpose, experimental and comparison interventions and their characteristics, number of participants in each group and their characteristics, frequency of the interventions (if applicable), follow-up intervals (if applicable), outcomes measures, main findings and authors' conflict of interest.
Risk of bias within included studies and quality of evidence assessment
The risk of bias within included studies will be assessed using the PEDRO scale. Reporting of the following aspects will be assessed: eligibility criteria, random allocation, concealed allocation, similarity between groups at baseline, blinding of subjects, therapists and assessors, attrition rate <15%, analysis by intention to treat, between-group comparison, and both point estimate and variability measures.
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[25] Sensitivity analyses will be conducted by the quality of studies, and by the length of follow-up. If possible, we will conduct sub-group analysis based on the type of the disorder (i.e. acute, sub-acute or chronic non-specific low back pain).
The strength of evidence will be assessed using the Grades of Recommendation, Assessment, Development and Evaluation (GRADE) approach.
[26] The GRADE approach uses four quality levels: high, moderate, low and very low. The strength of evidence will be downgraded by one level according to the following criteria: (1) limitations in the design and implementation of available studies suggesting risk of bias, (2) indirectness of evidence, (3) unexplained heterogeneity or inconsistency, (4) imprecision of results, and (5) high probability of publication bias.
If meta-analysis is not possible, we will present a narrative synthesis of findings for data analysis. In this case, quantitative findings for each study will be descriptively reported and summarized.
Ethics and dissemination
This systematic review has been prospectively registered at the PROSPERO (CRD42017077888).
The results of this review will be published in an international peer-reviewed journal.
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Selection process 11b State the process that will be used for selecting studies (such as two independent reviewers) through each phase of the review (that is, screening, eligibility and inclusion in meta-analysis)
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Risk of bias in individual studies 14 Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the outcome or study level, or both; state how this information will be used in data synthesis 
This systematic review will aim to assess the effectiveness of extrinsic biofeedback for reducing 7 pain, disability and recurrence of pain in patients with non-specific low back pain. 8
Methods and analysis: Systematic searches will be performed in CINAHL, Embase, Medline, 9
PsycInfo, Scopus and Web of Science. We will include randomized controlled trials that have: 10 recruited patients with non-specific low back pain; compared extrinsic feedback vs. either: 11 placebo or control; another intervention; or in addition to an intervention vs. that intervention 12 alone; and have used pain, disability scores or low back pain recurrence as outcome measures. 13
We will exclude studies with designs other than randomized controlled trials. We will assess the 14 risk of bias within included studies using the PEDro scale, and the strength of evidence using the 15
Grades of Recommendation, Assessment, Development and Evaluation (GRADE) approach. 16
Ethics and dissemination: Ethical approval and patient consent are not required since this is a 17 systematic review based on published studies. The results of this study will be published in an 18 international peer-reviewed journal. 19
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Methods
83
Patient and Public Involvement
84
Patients and or public were not involved with the development this research project. 85
Design
86
This study will be a systematic review with meta-analysis, if data allow, and will be based on the 87
PRISMA-P checklist.[22] 88 89
Types of studies 90 We will include randomised controlled trials, and exclude narrative reviews, systematic reviews, 91 non-randomised clinical trials, cross sectional studies and observational studies. We will not 92 impose language restrictions. 93
94
Types of participants
95
Studies must have recruited symptomatic individuals with non-specific low back pain (acute, 96 subacute or chronic), aged between 18 and 65 years. We will exclude studies involving patients 97 with specific or systematic diseases (e.g. tumours, cauda equina syndrome, fracture, 98 inflammatory arthropathy). 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
Types of interventions
101
Any interventions that include the use of any form of extrinsic biofeedback (e.g. verbal, tactile, 102 pressure biofeedback, electromyography feedback, body positional biofeedback, or other type 103 of feedback) will be included in this review. We will exclude studies focusing on behavioural 104 feedback or ergonomic training. Studies must include at least one of the following comparators: 105
Types of outcome measures
110
We will consider the following primary outcome measures: (1) assessed by a clinical researcher). We will consider motor performance tests as secondary 115 outcomes. Motor performance must be assessed using a form of biofeedback or 116 electromyography pre-and post-intervention. 117
118
Searches
119
Systematic searches will be performed in the following databases from the inception: CINAHL, 120
Embase, Medline, PsycInfo, Scopus and Web of Science. Search strategy is presented in Table 2 . 121
This search strategy was developed in consultation with a health sciences librarian, tested and 122 used for a review previously conducted by our research team. [17] 123 
125
After the exclusion of duplicates, two independent reviewers will conduct title, abstract and full 126 text screening against inclusion criteria. If any disagreement persists, a third reviewer will 127 adjudicate. The reference lists of included studies will be screened for additional relevant 128
studies. 129 130
Data extraction and management
131
Data will be extracted by two reviewers independently and compared. If any disagreements 132 persist and cannot be resolved by consensus, a third reviewer will be consulted. We will extract 133 the following data: authors, year of publication, country of origin, study design, study purpose, The risk of bias within included studies will be assessed using the PEDro scale. Reporting of the 141 following aspects will be assessed: eligibility criteria, random allocation, concealed allocation, 142 similarity between groups at baseline, blinding of subjects, therapists and assessors, attrition 143 rate <15%, analysis by intention to treat, between-group comparison, and both point estimate 144 and variability measures. 145
146
Data synthesis and analysis
147
If possible, we will use RevMan statistical software 5.3 (The Nordic Cochrane Centre) for 148 conducting the meta-analysis using a random-effects model. For the purpose of this review, 149 outcome measures will be categorized into the following based on time points of assessment: 150 immediate (within 2 weeks of the intervention delivery), short-term (2-13 weeks after 151 intervention delivery), medium-term (14-50 weeks after intervention delivery), and long-term 152 effects (51 or more weeks after intervention delivery). For the purpose of this review, the effect 153 For continuous data, we will calculate the mean difference (MD), and 95% confidence interval 157 (CI) if outcome measure scales are the same. In the case of different outcome measure scales, we 158 will calculate the mean difference (SMD), and 95% CI. We will assess heterogeneity using I 2 159 statistics[25 26] and will consider heterogeneity to be substantial if I 2 ranges from 50% to 160 90%.
[27] Sensitivity analyses will be conducted by the quality of studies, and by the length of 161 follow-up. If possible, we will conduct sub-group analysis based on the type of the disorder (i.e. 162 acute, sub-acute or chronic non-specific low back pain). 163
164
The strength of evidence will be assessed using the Grades of Recommendation, Assessment, 165
Development and Evaluation (GRADE) approach.
[28] The GRADE approach uses four quality 166 levels: high, moderate, low and very low. The strength of evidence will be downgraded by one 167 level according to the following criteria: (1) limitations in the design and implementation of 168 available studies suggesting risk of bias, (2) indirectness of evidence, (3) unexplained 169 heterogeneity or inconsistency, (4) imprecision of results, and (5) high probability of 170 publication bias. 171
172
If meta-analysis is not possible, we will present a narrative synthesis of the findings. In this case, 173 quantitative findings for each study will be descriptively reported and summarized. 174
175
Ethics and dissemination
176
This systematic review has been prospectively registered at the PROSPERO (CRD42017077888). 177
The results of this review will be published in an international peer-reviewed journal. 178 179
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